Hepatology international · 2026
Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yan Taotao, Tsai Pei-Chien, Yeh Ming-Lun, Jun Dae Won, Toyoda Hidenori, Hsu Yao-Chun, Leong Jennifer, Wang Xiaozhong, Qiang Xu, Abe Hiroshi, Suzuki Takanori, Dai Chia-Yen, Huang Jee-Fu, Chuang Wan-Long, Huang Chung-Feng, Chen Yao-Li, Lin Ping-Yi, Yasuda Satoshi, Liu Joanne Kimiko, Maeda Mayumi, Ogawa Eiichi, Tseng Cheng-Hao, Buti Maria, Vutien Philip, Wong Yu Jun, Trinh Huy, Honda Takashi, Uojima Haruki, Enomoto Masaru, Tanaka Yasuhito, Schwartz Myron, Cheung Ramsey, Yu Ming-Lung, Nguyen Mindie H
Аннотация
BACKGROUND: Antiviral treatment can reduce mortality of viral hepatocellular carcinoma (HCC), but may be underutilized.
METHODS: In a multinational real-world consortium of HCC patients with hepatitis B (HBV-HCC) or C (HCV-HCC), we assessed nucleos(t)ide analog treatment rate in HBV-HCC (2007-2023) and direct acting antiviral treatment rate in HCV-HCC (2015-2023).
RESULTS: Among 3973 HCC patients (3186 HBV, 647 HCV, 140 HBV/HCV), 49.7% of HBV-HCC and 63.2% of HCV-HCC received antiviral treatment. For HBV, lower treatment rates were observed in female (41.7% vs. 51.8%), older (> 60) (45.3% vs. 54.5%), non-cirrhosis and decompensated cirrhosis (vs. compensates cirrhosis: 41.3% vs. 43.2% vs. 76.7%), and Asia region (37.9% vs. 85.0%) patients; for HCV, lower rates in male (59.0% vs. 72.4%), compensated and decompensated cirrhosis (vs. noncirrhosis: 62.9% vs. 54.0% vs. 73.2%), and non-Asia region (58.2% vs. 69.9%) patients. Child A cirrhosis and Barcelona Clinic Liver Cancer (BCLC) 0/A patients had highest treatment rates followed by Child B and C or BCLC B, C, or D for both HBV (78.6%, 48.3%, 43.8%; 59.9%, 50.9%, 36.7%, 41.0%) and HCV (68.2%, 53.3%, 38.6%; 72.5%, 53.3%, 51.9%, 30.2%), all P<0.001. Factors independently associated with lower treatment rates were: female, age>60, Asia region, noncirrhosis, and BCLC B or C (vs. 0/A) for HBV; male, age>65, Child B or C cirrhosis (vs. noncirrhosis), and BCLC B or C for HCV. Antiviral treatment was independently associated with reduced mortality in both HBV-HCC and HCV-HCC patients.
CONCLUSION: Despite survival benefits, antiviral therapies were substantially underutilized in both HBV-HCC and HCV-HCC, particularly advanced patients.
METHODS: In a multinational real-world consortium of HCC patients with hepatitis B (HBV-HCC) or C (HCV-HCC), we assessed nucleos(t)ide analog treatment rate in HBV-HCC (2007-2023) and direct acting antiviral treatment rate in HCV-HCC (2015-2023).
RESULTS: Among 3973 HCC patients (3186 HBV, 647 HCV, 140 HBV/HCV), 49.7% of HBV-HCC and 63.2% of HCV-HCC received antiviral treatment. For HBV, lower treatment rates were observed in female (41.7% vs. 51.8%), older (> 60) (45.3% vs. 54.5%), non-cirrhosis and decompensated cirrhosis (vs. compensates cirrhosis: 41.3% vs. 43.2% vs. 76.7%), and Asia region (37.9% vs. 85.0%) patients; for HCV, lower rates in male (59.0% vs. 72.4%), compensated and decompensated cirrhosis (vs. noncirrhosis: 62.9% vs. 54.0% vs. 73.2%), and non-Asia region (58.2% vs. 69.9%) patients. Child A cirrhosis and Barcelona Clinic Liver Cancer (BCLC) 0/A patients had highest treatment rates followed by Child B and C or BCLC B, C, or D for both HBV (78.6%, 48.3%, 43.8%; 59.9%, 50.9%, 36.7%, 41.0%) and HCV (68.2%, 53.3%, 38.6%; 72.5%, 53.3%, 51.9%, 30.2%), all P<0.001. Factors independently associated with lower treatment rates were: female, age>60, Asia region, noncirrhosis, and BCLC B or C (vs. 0/A) for HBV; male, age>65, Child B or C cirrhosis (vs. noncirrhosis), and BCLC B or C for HCV. Antiviral treatment was independently associated with reduced mortality in both HBV-HCC and HCV-HCC patients.
CONCLUSION: Despite survival benefits, antiviral therapies were substantially underutilized in both HBV-HCC and HCV-HCC, particularly advanced patients.